Molecular Oncology

Selected Publications

1.    Sandip K. Mishra, Zhibo Yang, Abhijit Mazumdar, Amjad H. Talukder, Louise Larose, and Rakesh Kumar (2004) Metastatic Tumor Antigen 1 Short Form (MTA1s) Associates with Casein Kinase I- g2, an Estrogen-responsive Kinase. Oncogene 23(25):4422-4429.  

2.    Sandip K Mishra, Balssenthil S, Nguyen D, Vadlamudi RK (2004) Cloning and functional characterization of PELP1/ MNAR promoter. Gene 330:115-122.  

3.    Sandip K. Mishra, Amjad H. Talukder,  Anupama E. Gururaj, Zhibo Yang, Rajesh Singh, My G.Mahony, Clara Franci, Ratna Vadlamudi and Rakesh Kumar(2004) Upstream Determinants of Estrogen Receptor-a Regulation of  Metastatic Tumor Antigen 3 Pathway.MTA3 pathway. Journal of Biological Chemistry 279:32709-32715.  

4.    Talukdar AH*, Sandip K  Mishra*, Mandal M, Balasenthil S, Mehta S, Sahin AA, Barnes CJ, Kumar R.  (2003) MAT1 interacts with the MTA1, a CAK complex ring finger factor, and regulates estrogen receptor transactivation functions. Journal of Biological Chemistry 278: 11676-11685. (* Equal first author). 

5.    Sandip K Mishra, Mazumdar A, Vadlamudi RK, Li F, Wang RA, Yu W, Jordan C, Santen RJ, Kumar R (2003) MICoA, a novel Metastasis-associated protein 1 (MTA1) interacting coactivator, regulates Estrogen Receptor-a transactivation functions. Journal of Biological Chemistry 278: 19209-19219. 

6.    Sujit Nair, Sandip K. Mishra, Zhibo Yang, Seetharaman Balasenthil, Rakesh Kumar and Ratna K. Vadlamudi (2004) Potential Role of a Novel Coactivator PELP1 in Histone H1 displacement in Cancer. Cancer Research 64: 6416-6423.  

7.    Amjad H. Talukder, Anupama E. Gururaj, Sandip K. Mishra, Ratna Vadlamudi, and Rakesh Kumar (2004) Metastasis-Associated Protein 1 (MTA1) Interacts with NRIF3, an Estrogen-inducible Nuclear Receptor Coregulator. Molecular and Cellular Biology 24:6581-6591.  

8.    Barnes CJ, Vadlamudi RK, Sandip K. MIshra, Jacobson RH, Li F. and Kumar R (2003) Functional inactivation of a transcriptional corepressor by a signaling kinase. Nature Structural Biology 10:622-628. 

9.    Cheema SK, Sandip K. Mishra, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G (2003) PAR-4 transcriptionally regulates Bcl-2 through a WT1 binding site on the bcl-2 promoter. Journal of Biological Chemistry 278: 19995- 20005. 

10.  Li F., Mandal M., Sandip K Mishra , Barnes CJ, Kumar R (2002) Heregulin promotes expression and subcellular redistribution of ADP- ribosylation factor 3. FEBS Letters 524: 49-53.  

11.  Sandip K Mishra, Mandal M, Mazumdar A and Kumar R (2001) Dynamic chromatin remodeling on the HER2 promoter in human breast cancer. FEBS Letters 507: 88-94.  

12.  Mazumdar A*, Wang RA*, Sandip K Mishra, Adam L, Bagheri-Yarmand R, Mandal  M, Vadlamudi RK, Kumar R (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology 3: 30-37. * Equal contribution. 

13.  Talukder AH, Jorgensen HF, Mandal M, Sandip K Mishra, Vadlamudi RK, Clark BF, Mendelsohn J, Kumar R. (2001) Regulation of elongation factor-1 alpha expression by growth factors and antireceptor blocking antibodies. Journal of Biological Chemistry 278: 5636-5642. 

14.  Sheela, P, Sandip K. Mishra and A. Mahadevan. (2001) Detection and analysis        of chromosomal arsenic resistance in Pseudomonas fluorescens strain MSP3. Biochemical and Biophysical Research Communications 280: 1393 – 1401. 

15.  Sheela, P, Sandip K Mishra and A. Mahadevan. (2001) Functional analysis of a chromosomal arsenic resistance operon in Pseudomonas fluorescens strain MSP3. Molecular Biology Reports 28: 63-72. 

Awards

Amgen award in Basic Science Research (2003) at UT MD Anderson Cancer Center, Houston, Texas.  

Research Interest: Chromatin Remodeling in Breast Cancer

• To identify major coregulators in ER-a or mutated ER-a mediated breast cancer development and their anti-estrogen resistance.

• To determine whether the altered association coregulators with ER-a and alterations in their cross talk is responsible for hypersensitivity of ER-a.

• To determine whether any change in target promoters of ER-a of and investigate their possible implications for the global effect of hypersensitive ER-a.

• To identify the important altered associations and altered targets (promoter) as the mechanism underlying ER-a hypersensitivity.

• To manipulate such alterations at the molecular level in an effort to reverse the hypersensitivity of ER-a and its resistance to anti-estrogen.

Employment:

(1)  Scientist-D: Institute of Life Sciences, Bhubaneswar, India, since September 2007

(2)  Instructor: Department of Neurosurgery,  University of Texas MD Anderson Cancer Center, Houston, TX-77030, USA, September 2004- August 2007

(3)  Reader: Institute of Life Sciences, Bhubaneswar 2004

(4)  Post doctoral fellow: Dept. Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX-77030, USA, Jan 2000 - Jan 2004.

(5)  Project Associate: Eukaryotic Gene Expression Laboratory, National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi 110067, INDIA. Period: 1998 -1999.